1 / 4

Subcutaneous Biologics Market is Expected to Gain Popularity Across the Globe by 2026

Biologic, also known as biopharmaceutical, is a complex medicinal product manufactured by a biological process<br>

rushi12
Download Presentation

Subcutaneous Biologics Market is Expected to Gain Popularity Across the Globe by 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Subcutaneous Biologics Market - Size, Share, Subcutaneous Biologics Market - Size, Share, Growth, Outlook, and Opportunity Analysis, Growth, Outlook, and Opportunity Analysis, 2018-2026 2018-2026 Biologic, also known as biopharmaceutical, is a complex medicinal product manufactured by a biological process. Examples of biologics include blood and plasma derived products, vaccines, somatic cells and body proteins. Biologics market refers to a multibillion dollar opportunity that is expanding globally at an impressive growth rate. Most biologic products are given intravenously. However, in the past few years, a number of biologics have been developed that are given subcutaneously. The subcutaneous route of administration offers significant advantages over intravenous administration such as ease of drug administration, does not require skilled personnel for drug administration, enables at-home drug delivery and thus reduces patient time at healthcare facilities, reduced medicine cost and increased therapy compliance. Owing to aforementioned factors, the subcutaneous route of administration has gained enormous traction in recent years. Subcutaneous route of drug administration are highly effective in administering biologics such as vaccines, proteins, peptides, antibodies and other large and complex molecules. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/74 Subcutaneous Biologics Market Taxonomy Humira (Adalimumab), MabThera/Rituxan (Rituximab), Zytux (Rituximab), Stelara (ustekinumab), Enbrel (Etanercept)., Neulasta (filgrastim), ORENCIA (abatacept), RoACTEMRA (tocilizumab) and Herceptin (Trastuzumab) are among the major commercially available biologics that are administered through subcutaneous route. F. Hoffmann-La Roche AG announced the European Commission (EU) approval of its subcutaneous formulation of RoACTEMRA (tocilizumab) in April 2014. Amgen launched Neulasta delivery kit in 2015 to automate the delivery of drug and preventing infection in cancer patients. The global market for subcutaneous biologics has been segmented by the aforementioned biologic brands. On the basis of subcutaneous drug delivery systems, the market is categorized as:

  2. Increase in Awareness and the number of Diagnosed cases will Drive Demand in Developing Regions In terms of geography, the global market for subcutaneous biologics is segmented into four major regions, namely, North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). There is huge healthcare spending in countries such as United States and Canada, and high prevalence of diseases such as rheumatoid arthritis and breast cancer. The Centers for Disease Control and Prevention (CDC) estimate that the current prevalence of rheumatoid arthritis (nearly 50 million Americans in 2012) will increase to 78 million by 2040. The disease also affects nearly 300,000 children in the U.S. according to RheumatoidArthritis.org. In the European region, EU-5 countries (Germany, France, United Kingdom, Italy and Spain) are the most potential market owing well established economy of these regions. Convenient drug delivery format is also in demand in developing regions such as Asia Pacific and Latin America where therapy compliance is a major issue. Large undiagnosed population, inadequate access to medicines and affordability issues hinder the market growth for subcutaneous biologics in developing regions. Report includes chapters which deeply display the following deliverable about industry : • Subcutaneous Biologics Market Research Objective and Assumption • Subcutaneous Biologics Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Subcutaneous Biologics Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Subcutaneous Biologics Market, By Regions • Subcutaneous Biologics Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Subcutaneous Biologics Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Subcutaneous Biologics Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Subcutaneous Biologics Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion

  3. Some of the major companies operating in the global subcutaneous biologics market include Genentech Inc., Biogen Idec, F. Hoffmann-La Roche AG, Amgen, Inc., Eisai, Inc., AbbVie, Inc., Pfizer Ltd., Takeda Pharmaceutical Company Ltd. and Bristol-Myers Squibb. Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/74 Prefilled syringes Wearable injectors Auto-injectors Drug reconstitution delivery systems. • • • The subcutaneous biologics market is also analyzed based on the applications as follows: Crohn’s Disease Rheumatoid Arthritis Breast cancer Leukemia Lymphoma Psoriasis • • • • • • About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702

  4. Email: sales@coherentmarketinsights.com

More Related